SBIR/STTR Research Award
A Panel-Based Approach to the Diagnosis of Genetic Nephropathies Utilizing Next G
Award amount
$143,382Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Nephropathology Associates, PLC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- LFE7CWNKK1X3
- Solicitation number
- PA13-234
- Topic code
- NIDDK
Research abstract
DESCRIPTION (provided by applicant): There are currently mutations in over 200 genes that have been described to cause kidney disease. Current strategies for diagnosis of genetic kidney disease are extremely costly and time consuming. We aim to develop a comprehensive next generation sequencing panel that can simultaneously test for all currently described kidney- associated gene mutations at a low price within approximately 2 weeks. There are currently no comprehensive gene panels commercially available inthe field of nephrology. We believe this assay will greatly decrease turnaround time and cost for the diagnosis of disease. Once the nephrology gene panel is developed, we will use it to describe genotypic-phenotypic correlations in a large cohort of patients with unexplained chronic kidney disease. We will isolate DNA from de-identified renal biopsy samples and use these samples for target enrichment, amplification and labeling of the exons of genes in our panel followed by sequencing on a MiSeq. We
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases
- Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy
- Smartphone image analysis for real time adequacy assessment during kidney biopsy
- Development of specific peptide reagents for serologic monitoring of Exostosin autoantibodies in membranous lupus nephritis
- Rapid Genotyping of ApoL1 Risk Alleles using CRISPR-Cas12a
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b
- Wearable Metabolic Sensor for Monitoring of Lactate and Glucose for People with Diabetes
- Novel Over-the-Scope Platform for Control of Variceal Bleeding
- Tolerogenic Nanotherapy to Delay Type I Diabetes
- An intravascular Bioartificial Pancreas (iBAP)
Research funding history
9 SBIR/STTR records share this UEI (2004–2023). Reported award amounts total $5,570,360. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services